Financial stress is mounting as total debt surged from $15.2 million in 2023Q4 to $231.9 million in 2026Q1, contributing to a contraction in the equity base to $662.0 million.
| Total Current Assets | 944.73M | 1.02B | 1.05B | 939.61M | 1.12B | 1.5B | 1.22B | 292.46M | 269.14M | 230.61M | 84.09M | 13.23M |
| Cash & Short-Term Investments | 661.32M | 689.57M | 779.67M | 806.45M | 1.01B | 1.41B | 1.19B | 275.93M | 263.3M | 229.66M | 83.95M | 13.16M |
| Cash Only | 651.32M | 679.57M | 449.67M | 790.15M | 1.01B | 964.1M | 442.12M | 75.93M | 62.95M | 229.66M | 83.95M | 13.16M |
| Short-Term Investments | 10M | 10M | 330M | 16.3M | 0 | 445M | 744.68M | 200M | 200.35M | 0 | 0 | 0 |
| Accounts Receivable | 54.07M | 106.12M | 89.41M | 65.33M | 48.57M | 54.81M | 5.17M | 3.79M | 90K | 0 | 0 | 0 |
| Days Sales Outstanding | 73.38 | 84.17 | 81.79 | 89.41 | 82.44 | 138.63 | 38.51 | 106.56 | 253.76 | - | - | - |
| Inventory | 85.96M | 74.75M | 39.88M | 44.83M | 31.62M | 18.95M | 13.14M | 6M | 3.82K | 0 | 0 | 0 |
| Days Inventory Outstanding | 138.5 | 142.78 | 98.43 | 170.76 | 155.93 | 132.41 | 20.04 | 584.67 | 32 | - | - | - |
| Other Current Assets | 143.38M | 148.85M | 141.53M | 23M | 35.67M | 0 | 0 | 0 | -603 | 0 | 0 | 0 |
| Total Non-Current Assets | 151.01M | 153.1M | 135.27M | 96.69M | 95.8M | 109.08M | 81.6M | 62.69M | 32.84M | 19.02M | 4.81M | 710.11K |
| Property, Plant & Equipment | 64.65M | 66.54M | 69.47M | 68.69M | 78.77M | 58.28M | 47.14M | 36.86M | 20.77M | 11.98M | 2.66M | 707.58K |
| Fixed Asset Turnover | 6.90x | 6.92x | 5.74x | 3.88x | 2.73x | 2.48x | 1.04x | 0.35x | 0.01x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 75.76M | 76.14M | 58.93M | 16.46M | 8.4M | 9.66M | 9.44M | 8.8M | 321.57K | 20.09K | 7K | 2.52K |
| Long-Term Investments | 1.11M | 0 | 3.12M | 9.22M | 6.43M | 15.61M | 1.28M | 2.4M | 3.15M | 1.65M | 500K | 0 |
| Other Non-Current Assets | 7.15M | 7.02M | 3.75M | 2.32M | 2.2M | 25.53M | 23.75M | 14.62M | 8.88M | 5.5M | 3.06M | 0 |
| Total Assets | 1.1B | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B | 1.3B | 355.15M | 301.99M | 249.63M | 88.91M | 13.94M |
| Asset Turnover | 0.39x | 0.39x | 0.34x | 0.26x | 0.18x | 0.09x | 0.04x | 0.04x | 0.00x | - | - | - |
| Asset Growth % | 27.78% | -1.13% | 14.42% | -15.07% | -24.21% | 24.07% | 265.37% | 17.61% | 20.97% | 180.78% | 537.79% | - |
| Total Current Liabilities | 392.98M | 416.17M | 299.38M | 203.07M | 139.84M | 192.9M | 98.04M | 46.63M | 48.84M | 12.07M | 5.17M | 3.94M |
| Accounts Payable | 126.17M | 141.61M | 100.91M | 112.99M | 65.97M | 126.16M | 62.64M | 22.66M | 37.43M | 8.97M | 523.34K | 1.45M |
| Days Payables Outstanding | 227.13 | 270.5 | 249.09 | 430.43 | 325.33 | 881.52 | 95.49 | 2.21K | 313.44K | - | - | - |
| Short-Term Debt | 219.8M | 210.87M | 131.71M | 0 | 0 | 0 | 0 | 6.45M | 3.64M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 55.96M | 27.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 18.38M | 36.35M | 6.35M | 5.35M | 4.05M | 4.42M | 4.57M | 2.39M | 2.5M | 778.96K | 4.05M | 2.14M |
| Current Ratio | 2.40x | 2.45x | 3.51x | 4.63x | 8.04x | 7.78x | 12.40x | 6.27x | 5.51x | 19.11x | 16.25x | 3.36x |
| Quick Ratio | 2.19x | 2.27x | 3.38x | 4.41x | 7.81x | 7.68x | 12.27x | 6.14x | 5.51x | 19.11x | 16.25x | 3.36x |
| Cash Conversion Cycle | -15.25 | -43.55 | -68.86 | -170.26 | -86.96 | -610.48 | -36.94 | -1.52K | -313.15K | - | - | - |
| Total Non-Current Liabilities | 40.77M | 40.72M | 45.47M | 37.11M | 34.7M | 37.1M | 30.25M | 13.86M | 2.06M | 2.39M | 135.29M | 28.37M |
| Long-Term Debt | 12.11M | 13.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 22.15M | 0 | 13.71M | 8.05M | 13.34M | 9.61M | 13.39M | 10.98M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 28.67M | 27.33M | 325K | 325K | 0 | 0 | 0 | 0 | 0 | 0 | 134.51M | 28.31M |
| Total Liabilities | 433.76M | 456.88M | 344.86M | 240.18M | 174.54M | 230M | 128.29M | 60.49M | 50.91M | 14.46M | 140.46M | 32.31M |
| Total Debt | 231.91M | 224.26M | 153.47M | 15.15M | 20.39M | 15.54M | 18.6M | 21.78M | 3.64M | 0 | 0 | 0 |
| Net Debt | -419.41M | -455.31M | -296.2M | -775M | -988.08M | -948.56M | -423.52M | -54.15M | -59.31M | -229.66M | -83.95M | -13.16M |
| Debt / Equity | 0.35x | 0.31x | 0.18x | 0.02x | 0.02x | 0.01x | 0.02x | 0.07x | 0.01x | - | - | - |
| Debt / EBITDA | -1.02x | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.85x | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -30.73x | -33.26x | -113.07x | - | - | - | -1667.41x | -662.20x | -3489.82x | - | - | - |
| Total Equity | 661.98M | 715.5M | 840.9M | 796.12M | 1.05B | 1.38B | 1.17B | 294.66M | 251.08M | 235.17M | -51.55M | -18.37M |
| Equity Growth % | -7.01% | -14.91% | 5.62% | -23.86% | -24.23% | 18.01% | 296.85% | 17.36% | 6.77% | 556.18% | -180.63% | - |
| Book Value per Share | 5.98 | 6.53 | 8.50 | 82.38 | 109.14 | 148.39 | 150.56 | 45.78 | 47.73 | 108.11 | -54.62 | -21.13 |
| Total Shareholders' Equity | 661.98M | 715.5M | 840.9M | 796.12M | 1.05B | 1.38B | 1.17B | 294.66M | 251.08M | 235.17M | -51.55M | -18.37M |
| Common Stock | 7K | 7K | 7K | 6K | 6K | 6K | 5K | 4K | 3.48K | 3K | 579 | 533 |
| Retained Earnings | -2.68B | -2.63B | -2.45B | -2.2B | -1.86B | -1.42B | -713.6M | -444.7M | -249.63M | -110.55M | -60.17M | -22.66M |
| Treasury Stock | 0 | 0 | -20.84M | -20.84M | -11.86M | -4.28M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 15.11M | 29.7M | 50.52M | 37.63M | 25.68M | -23.64M | -14.52M | 4.62M | 2.66M | 449.91K | -698.53K | -103.62K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent Capital Market Dependency
According to reported financial statements, Zai Lab's equity base has contracted from $796.1 million in 2023Q4 to $662.0 million by 2026Q1, reflecting a persistent trend of value erosion driven by the company's inability to achieve operational profitability while funding its extensive R&D and commercial infrastructure.
The consistent decline in equity, coupled with a ballooning accumulated deficit of $2.7 billion, suggests that the company is consuming its capital base to sustain its current business model. Investors should monitor whether this trajectory necessitates further dilutive financing, as the current rate of equity depletion appears unsustainable without a fundamental shift in revenue generation.
Based on recent SEC filings, Zai Lab's total debt has surged from $15.2 million in 2023Q4 to $231.9 million in 2026Q1, indicating a shift toward debt-based financing as the company attempts to bridge the gap between its high operational burn rate and limited internal cash generation.
The increase in the debt-to-equity ratio to 0.35 suggests that the company is increasingly relying on leverage to maintain its operations. This rising debt burden warrants further investigation, as it introduces interest expense pressures that may further constrain the company's already negative operating margins.
As reported in quarterly filings, Zai Lab's cash position has declined from a peak of $790.2 million in 2023Q4 to $651.3 million in 2026Q1, while the current ratio has compressed from 4.63 to 2.40, signaling a tightening of the company's short-term financial flexibility.
While a current ratio of 2.40 still provides a nominal buffer, the rapid compression of this metric suggests that the company's liquidity is being consumed faster than it is being replenished. This trend may indicate that the firm is approaching a point where its cash runway could become a primary concern for stakeholders.
Data from the balance sheet shows that goodwill has increased from $16.5 million in 2023Q4 to $75.8 million in 2026Q1, which may indicate that the company is capitalizing acquisition costs that could be subject to future impairment if licensed assets fail to meet commercial expectations.
The accumulation of goodwill in a business model heavily reliant on external licensing suggests that the company's asset quality is sensitive to the success of its partners' clinical programs. Investors should be wary that these intangible assets may not represent tangible value if the underlying drug candidates face regulatory or market adoption hurdles.
Quick answers to the most common questions about buying ZLAB stock.
As of 2025, Zai Lab Limited (ZLAB) had total assets of $1.17B including $1.02B in current assets.
Zai Lab Limited (ZLAB) carries total debt of $224.3M, offset by $689.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Zai Lab Limited (ZLAB) has total shareholders' equity (book value) of $715.5M ($6.53 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Zai Lab Limited (ZLAB) reported a current ratio of 2.45x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.